We are live on ! Find out more
ZEAL

Zealand Pharma A/S American Depositary Shares
ZEAL

Delisted

ZEAL was delisted on the 29th of September, 2022.

Back to rankings

14 hedge funds and large institutions have $61.4M invested in Zealand Pharma A/S American Depositary Shares in 2020 Q4 according to their latest regulatory filings, with funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 14 → 14 (0)

0% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 4

3% less capital invested

Capital invested by funds: $63.4M → $61.4M (-$2M)

Holders
14
Holders Change
–
Holders Change %
0%
% of All Funds
0.25%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
4
Reduced
4
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Wellington Management Group
Wellington Management Group
Massachusetts
+$1.22M
2
Jane Street
Jane Street
New York
+$352K
3
FCM
Farallon Capital Management
California
+$188K
4
Bank of America
Bank of America
North Carolina
+$3.61K

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$226K
2
JP Morgan Chase
JP Morgan Chase
New York
-$14.3K
3
Morgan Stanley
Morgan Stanley
New York
-$3.91K
4
US Bancorp
US Bancorp
Minnesota
-$1.73K

ZEAL Hedge Fund Activity: Q4 2020 in Review

14 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in Zealand Pharma A/S American Depositary Shares (ZEAL) for Q4 2020, worth a combined $61.4M — down 3.2% from $63.4M a quarter earlier.

Fund positioning in ZEAL was balanced in Q4 2020: 0 funds opened new positions, 0 closed out, 4 added to existing stakes and 4 trimmed.

The largest buyer was Wellington Management Group, adding an estimated $1.22M. The largest seller was Renaissance Technologies, cutting an estimated $226K.

  • 14 institutional investors held Zealand Pharma A/S American Depositary Shares (ZEAL) as of Q4 2020, unchanged from Q3 2020.
  • Funds reported $61.4M of Zealand Pharma A/S American Depositary Shares stock for Q4 2020, down 3.2% quarter-over-quarter.
  • 0 funds opened new Zealand Pharma A/S American Depositary Shares positions in Q4 2020 and 0 closed out.
  • The largest Zealand Pharma A/S American Depositary Shares buyer in Q4 2020 was Wellington Management Group, an estimated $1.22M added.
  • The largest Zealand Pharma A/S American Depositary Shares seller in Q4 2020 was Renaissance Technologies, an estimated $226K sold.

Based on aggregated 13F filings for Q4 2020.